7216-18-4

Basic information

• Product Name: 1,2-TRIMETHYLENEDIOXYBENZENE
• Synonyms: 1,2-TRIMETHYLENEDIOXYBENZENE;OTAVA-BB BB7020410055;3,4-Dihydro-2H-1,5-benzodioxepine;3,4-dihydro-2h-5-benzodioxepin;Pyrocatechol trimethylene ether;1,5-benzodioxepane;3,4-Dihydro-2H-1,5-Benzodioxep;3,4-dihydro-2H-benzo[b][1,4]dioxepine
• CAS NO: 7216-18-4
• Molecular Formula: C₉H₁₀O₂
• Molecular Weight: 150.17
• Mol File: 7216-18-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 14-15℃
• Boiling Point: 221℃
• Flash Point: 92℃
• Appearance: /
• Density: 1.103
• Vapor Pressure: 0.163mmHg at 25°C
• Refractive Index: 1.5450
• Storage Temp.: Sealed in dry,Room Temperature
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 1,2-TRIMETHYLENEDIOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-TRIMETHYLENEDIOXYBENZENE(7216-18-4)
• EPA Substance Registry System: 1,2-TRIMETHYLENEDIOXYBENZENE(7216-18-4)

Safety Data

• RTECS: DF4725200
• Hazardous Substances Data: 7216-18-4(Hazardous Substances Data)

Usage

Uses

It is used as an active pharmaceutical intermediate.

InChI:InChI=1/C9H10O2/c1-2-5-9-8(4-1)10-6-3-7-11-9/h1-2,4-5H,3,6-7H2

Upstream product

• 120-80-9 benzene-1,2-diol 
• 109-64-8 1,3-dibromo-propane 
• 142-28-9 1,3-Dichloropropane 
• 76670-08-1 Potassium; 2-(3-bromo-propoxy)-phenolate 
• 51974-49-3 3-(2-hydroxyphenoxy)propyl bromide 

Downstream Products

• 123769-41-5 (4-Butyl-phenyl)-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-methanone 
• 111038-94-9 7-propionyl-1,5-benzodioxypane 
• 111039-00-0 (E)-1-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-3-phenyl-propenone 
• 123769-38-0 (3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-(4-fluoro-phenyl)-methanone 
• 123769-35-7 (2-Chloro-phenyl)-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-methanone 
• 123769-36-8 (4-Chloro-phenyl)-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-methanone 
• 123769-39-1 (3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-(4-methoxy-phenyl)-methanone 
• 123769-40-4 (3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-(4-nitro-phenyl)-methanone 
• 123769-33-5 (2-Bromo-phenyl)-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-methanone 
• 123769-34-6 (4-Bromo-phenyl)-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-methanone 
• 123769-37-9 (3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-(2-fluoro-phenyl)-methanone 
• 121364-94-1 7-phenylacetyl-2H-3,4-dihydro-1,5-benzodioxepine 
• 123769-43-7 (3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-naphthalen-2-yl-methanone 
• 78288-94-5 3,4-dihydro-7-nitro-2H-1,5-benzodioxepine 

Relevant articles and documents

Cyclization of 2-(3-halopropyloxy)phenoxide ions in functionalized surfactants

Observed rate constants (k(obs)) of cyclization of 2-(3-halopropyloxy)phenoxide (halo = bromo, iodo; PhBr7 and PhI7, respectively) in aqueous micelles of N-hexadecyl-N-(2-hydroxyethyl)-N,N-dimethylammonium bromide (1) depend on [1] and [NaOH]. The rate profiles go through a maximum and, at high [1], the catalytic effect is modest. By contrast, k(obs) in aqueous micelles of N-hexadecyl-N-(2-hydroxyethyl)-N,N-dimethylammonium sulfate (2) increases monotonically with increasing surfactant concentration and becomes constant at high [2]. 1H, 13C, and 14N NMR spectra of 1 and 2 show that micelles of 1 and 2 do not differ in dimension and shape and that the average conformations of 1 and 2 are similar.

AN IMPROVED METHOD FOR THE PREPARATION OF ALKYLENEDIOXYBENZENE COMPOUNDS

This invention relates to an improved method for preparing alkylenedioxybenzene compounds of Formula I, from the corresponding ortho-dihydroxy aromatic compound of Formula II wherein n is 0, 1, 2 or 3; and R1 and R2 independently represent H, linear or branched C1 – C10 alkyl or alkenyl group, cycloalkyl group, halogen selected from C1, Br, I, nitro (-NO2), alkoxy (-OR) or SR thioether (-SR), wherein R is linear or branched alkyl group comprising C1-C6 carbon atoms.

Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease

Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.